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To examine whether interictal plasma pituitary adenylate cyclase-activating peptide 38-like
immunoreactivity (PACAP38-LI) shows correlation with the microstructural integrity of the
white matter in migraine.
Methods
Interictal plasma PACAP38-LI was measured by radioimmunoassay in 26 patients with mi-
graine (24 women) who underwent diﬀusion tensor imaging afterward using a 1.5-tesla
magnetic resonance scanner. Data were analyzed using tract-based spatial statistics included in
FMRIB’s Software Library.
Results
Interictal plasma PACAP38-LI showed signiﬁcant correlation with mean diﬀusivity (p <
0.0179) mostly in the bilateral occipital white matter spreading into parietal and temporal white
matter. Axial and radial diﬀusivity showed positive correlation with interictal PACAP38-LI (p <
0.0432 and p < 0.0418, respectively) in the left optic radiation and left posterior corpus
callosum. Fractional anisotropy did not correlate signiﬁcantly with PACAP38-LI. With disease
duration as a nuisance regressor in the model, PACAP38-LI correlated with axial and mean
diﬀusivity in the left thalamus (p < 0.01).
Conclusion
We report a link between PACAP38, a pathobiologically important neurochemical biomarker,
and imaging markers of the disease that may bolster further research into the role of PACAP38
in migraine.
From the Departments of Neurology (D.V., N.S., J.T., A.K., P.F., K.K., E.T., B.K., L.V., Z.T.K.) and Radiology (Z.T.K.), Albert Szent-Gyo¨rgyi Clinical Center, University of Szeged, Hungary;
Central European Institute of Technology (N.S., A.K.), Brno, Czech Republic; MTA-SZTE Neuroscience Research Group (B.T., L.V.), Szeged; and Department of Pharmacology and
Pharmacotherapy, Faculty of Medicine (T.B., Z.H.), and Ja´nos Szenta´gothai Research Centre & Centre for Neuroscience (Z.H.), University of Pe´cs, Hungary.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Copyright © 2018 American Academy of Neurology 1
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Pituitary adenylate cyclase-activating peptide 38 (PACAP38)
is a neuropeptide of growing importance in migraine litera-
ture. There are consistent reports of its migraine-inducing
properties,1,2 and its blood levels correspond with headache
attacks, with decreased blood levels in the interictal term.3
The exact nature of its connection to migraine, however,
remains unclear. Research points to the involvement of
PACAP38 in the activation of the trigeminovascular system,4
and it has been aﬃliated with headache-related photophobia
as well.5
Alterations of brain function and structure in migraine were
identiﬁed with various MRI modalities. Magnetic resonance
spectroscopy studies demonstrated neurochemical diﬀer-
ences mainly in the cingulate and occipital cortices in patients
with migraine.6,7 Functional MRI studies found altered acti-
vation in regions related to pain processing, and the activity of
resting-state networks was also shown to be altered in mi-
graine.8 Several diﬀusion tensor imaging (DTI) studies found
microstructural abnormalities of the white matter in patients
with migraine in pathways related to pain sensation9 and vi-
sual processing.10 Since PACAP38 turns up as a functional
molecule in these systems,11,12 the question arises whether the
peptide’s assumed role in migraine pathophysiology is linked
to alterations of the white matter microstructure. A recent
study by Yilmaz et al.13 revealed increased ictal levels of S100B
(a marker of glial damage) and neuron-speciﬁc enolase (a
marker of neuronal damage) in migraineurs without aura.
Furthermore, infusion of PACAP38 in migraineurs changed
the plasma concentrations of S100B.14 Combined with de-
creased interictal levels of PACAP38, these results led us to
the hypothesis that PACAP38 may induce degenerative
changes in migraineurs that might be detectable with DTI.
Alternatively, PACAP38 also exerts neurotrophic and neu-
roprotective eﬀects,15,16 and these eﬀects might also be
detected by diﬀusion MRI.
Serum levels of PACAP38 seem to approximately represent
intracerebral PACAP38 metabolism in human studies since
PACAP38 passes through the blood-brain barrier by way of
a saturable transport mechanism,17 and there are also reports
of increased blood-brain barrier permeability in migraine.18
Since decreased interictal PACAP38 levels could hypotheti-
cally be a product of altered PACAP38 metabolism, which
might coexist with microstructural changes, we hypothesized
that interindividual variation of subnormal interictal
PACAP38 levels in patients with migraine might correlate
with microstructural characteristics. In this exploratory study,




We recruited 26 patients with migraine from outpatients of
the Headache Outpatient Clinic at the Department of
Neurology. Patients were diagnosed according to the In-
ternational Headache Society criteria.20 Participants were
screened for depression using the Hamilton Depression
Scale,21 and those with a test result of >8 points were
excluded. Apart from migraine, participants did not have
any neuropsychiatric illnesses. Of 26 patients, 8 received
prophylactic treatment for migraine (2 topiramate, 6
iprazochrome).
Standard protocol approvals, registrations,
and patient consents
The study was approved by the local ethics committee (87/
2009), and written consent was provided by all
participants.
Acquisition of MRI data
MRI scans took place in the interictal period, at least 1 week
after the last migraine attack, using a 1.5T GE Signa Excite
HDxt MRI Scanner (GE Healthcare, Milwaukee, WI). We
obtained 3-dimensional fast spoiled gradient echo images
(echo time = 4.1 milliseconds [ms]; repetition time = 10.276
ms; matrix: 256 × 256; ﬁeld of view: 25 × 25 cm; ﬂip angle:
15°; in-plane resolution: 1 × 1mm; slice thickness: 1 mm) and
60 directional diﬀusion-weighted images with 6 non-
diﬀusion-weighted reference volumes (echo time = 93.8 ms;
repetition time = 16 ms; matrix: 96 × 96; ﬁeld of view: 23 × 23
cm; ﬂip angle: 90°; in-plane resolution: 2.4 × 2.4 mm; slice
thickness: 2.4 mm; b = 1,000 s/mm2; number of excitations =
2; array spatial sensitivity encoding technique factor = 2) for
all participants, using similar parameters as published in our
recent study.22
PACAP38-like immunoreactivitymeasurements
Blood samples were drawn interictally from the cubital vein
just before MRI scans, while patients maintained a sitting
position. The samples were collected in cooled glass tubes,
which contained 12 mg of EDTA and aprotinin, a protease
inhibitor (Trasylol 1,200 IU; Bayer Pharmaceuticals Corp.,
West Haven, CT). We kept the tubes at 4°C before centri-
fugation and stored them at −80°C afterward pending
Glossary
AD = axial diﬀusivity; DTI = diﬀusion tensor imaging; FA = fractional anisotropy; FMRIB = Oxford Centre for Functional
Magnetic Resonance Imaging of the Brain; FSL = FMRIB’s Software Library; MD = mean diﬀusivity; PACAP38 = pituitary
adenylate cyclase-activating peptide 38; PACAP38-LI = pituitary adenylate cyclase-activating peptide 38-like immunoreactivity;
RD = radial diﬀusivity.
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PACAP38-like immunoreactivity (PACAP38-LI) measure-
ment with a speciﬁc and sensitive radioimmunoassay method
published earlier.3
The PACAP38 antiserum “88111-3” was raised against
synthetic peptides bound to bovine thyroglobulin or bovine
serum albumin in rabbits. The tracers were labeled with
mono-125I and prepared in our laboratory. As standards, we
used synthetic peptides in concentrations of 0 to 1,000
fmol/mL. We prepared the assay in 1 mL of 0.05 M (pH =
7.4) phosphate buﬀer that contained 0.1 M sodium
chloride, 0.25% (w/v) bovine serum albumin, and 0.05%
(wt/vol) sodium azide.
Following centrifugation at 2,000 rpm, 4°C, 10 minutes,
precipitation with absolute alcohol took place and after an-
other centrifugation at 2,000 rpm, 4°C for 10 minutes, we
dried the samples under nitrogen ﬂow and resuspended them
in 300 μL of assay buﬀer. Afterward, we measured the anti-
serum (100 mL, diluted 1:10,000), the tracer (100 mL, 5,000
cpm/tube), and the standard/unknown samples (100 mL)
into polypropylene tubes along with the assay buﬀer.
Table Clinical and demographic data of the patients











1 33 F MwoA 15 36 1 7 A
2 34 F MwoA 3 52 8 8 R
3 54 F MwoA 20 12 0 10 R
4 30 F MwA 16 18 2 6 L
5 29 F MwoA 18 36 2 8 L
6 38 F MwoA 30 60 6 9 A
7 53 F MwoA 24 12 10 5 L
8 23 F MwA 8 72 2 7 R
9 21 F MwoA 1 12 0 10 L
10 27 F MwoA 3 52 9 7 L
11 38 F MwoA 13 120 0 9 A
12 24 M MwA 7 1 0 7 R
13 44 F MwoA 32 24 2 9 A
14 37 F MwA 9 3 2 7 A
15 37 F MwoA 27 36 0 9 A
16 33 F MwoA 15 48 0 9 A
17 28 F MwoA 5 120 4 7 A
18 46 F MwoA 31 30 0 8 A
19 29 F MwA 10 6 2 8 A
20 35 F MwA 18 53 4 8 L
21 28 F MwoA 4 60 3 9 A
22 25 F MwoA 7 36 8 8 L
23 47 F MwoA 11 182 6 8 R
24 38 F MwoA 12 30 2 10 A
25 24 M MwA 11 8 0 6 A
26 42 F MwA 31 36 0 7 R




Abbreviations: A = alternating; MwA = migraine with aura; MwoA = migraine without aura; VAS = visual analog scale.
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Following incubation for 48 to 72 hours at 4°C, we separated
peptides bound by antibodies from free ones by way of adding
100 mL of separating solution (containing 10 g charcoal, 1 g
dextran, 0.5 g fat-free milk powder dissolved in 100 mL of
distilled water). After another centrifugation at 3,000 rpm,
4°C for 15 minutes, we carefully decanted the tubes’ contents
and measured the radioactivity of the precipitates in a gamma
counter (NZ310; Gamma, Budapest, Hungary). Finally, we
read the concentration values of PACAP38 in the unknown
samples from the calibration curves.
MRI analysis
We performed analysis of MRI data using FMRIB’s Software
Library (FSL version 5.0, fmrib.ox.ac.uk/fsl).23 The obtained
diﬀusion-weighted images underwent correction for eddy cur-
rents and movement artifacts using a 12 degrees of freedom
aﬃne linear registration to the ﬁrst reference volume without
diﬀusion weighting.24 Diﬀusion tensors were ﬁtted in each voxel
of the motion- and eddy-corrected diﬀusion data using the al-
gorithm included in FSL’s FDT (FMRIB’s Diﬀusion Tool-
box).25 We calculated fractional anisotropy (FA), mean
diﬀusivity (MD), and diﬀusivity parallel (λ1, axial diﬀusivity
[AD]) and perpendicular ([λ2 + λ3]/2, radial diﬀusivity [RD])
to the main direction of diﬀusion in the whole brain.
We performed statistical analysis of the FA data in each voxel
via tract-based spatial statistics.26 All participants’ FA data
were allineated into standard space using nonlinear registra-
tion as implemented in FSL’s FNIRT (FMRIB’s nonlinear
image registration tool),27 which uses a b-spline representa-
tion of the warp ﬁeld utilized during registration.28 Next,
a mean FA image was calculated and then thresholded at 0.2
to produce a mean FA skeleton representing the centers of
white matter tracts shared by the group. Each participant’s
aligned FA data were then projected onto the mean FA
skeleton, and the skeletonized images were fed into voxelwise
cross-subject statistics.
We calculated linear correlation between diﬀusion measures
(FA, MD, AD, RD) and PACAP38-LI in each voxel using
a standard general linear model design with permutation-
based cluster analysis as realized in FSL,29 with age and sex as
Figure 1 Correlation of PACAP38-LI and mean diffusivity
(A) The skeleton is overlaid in green on the mean fractional anisotropy image. Significant correlations are depicted in copper (maximum p value MNI
coordinates: x = 125, y = 69, z = 75). Clusters are thickened for better visualization. The color bar represents 1 − p values corrected formultiple comparisons. (B)
Scatterplot PACAP38-LI is plotted against average mean diffusivity under the significant voxels. The boxplots stand for mean, 95% confidence interval, and
range. Outliers are depicted with open circles. MNI = Montreal Neurological Institute; PACAP38-LI = pituitary adenylate cyclase-activating peptide 38-like
immunoreactivity.
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nuisance regressors in the model. Although no clinical varia-
bles correlated with interictal PACAP38-LI in the studied
patients, we also tested another model with disease duration
included as an additional nuisance regressor, as it was pre-
viously shown to correlate with interictal PACAP38-LI in
a larger sample of patients.3 Clusters were formed using the
threshold-free cluster enhancement method,30 and correction
for multiple comparisons was performed using FSL’s ran-
domise tool31 at a threshold of p < 0.05.
Data availability
Anonymized data will be shared on request through personal
correspondence after the approval of the local ethics committee.
Results
Demographic and clinical data of the patients
Twenty-six patients with migraine were recruited into the
study, 8 of whom had migraine with aura. Aura symptoms
were visual except for a male and a female patient who had
additional somatosensory symptoms. The demographic and
clinical data of the patients are summarized in the½T1 table.
Correlation of PACAP38-LI and white
matter microstructure
Interictal plasma PACAP38-LI showed signiﬁcant correlation
MD (p < 0.0179, corrected for multiple comparisons) in the
bilateral occipital white matter reaching into parietal and
temporal white matter ( ½F1ﬁgure 1).
The correlation with AD was signiﬁcant (p < 0.0432, cor-
rected for multiple comparisons) in the left optic radiation
and left posterior corpus callosum ( ½F2ﬁgure 2).
RD correlated with interictal PACAP38-LI (p < 0.0418, cor-
rected for multiple comparisons) in the left optic radiation
and parietal white matter ( ½F3ﬁgure 3). FA did not show any
signiﬁcant correlation with interictal PACAP38-LI.
Correlation of PACAP38-LI and diffusion
measures with disease duration as
nuisance regressor
With age, sex, and disease duration as nuisance regressors,
interictal PACAP38-LI showed signiﬁcant correlation with
MD and AD in the left thalamus (p < 0.01, corrected for
Figure 2 Correlation of PACAP38-LI and axial diffusivity
(A) The skeleton is overlaid in greenon themean fractional anisotropy image. Significant correlations aredepicted in red-yellow (maximum p valueMNI coordinates:
x = 125, y = 69, z = 75). Clusters are thickened for better visualization. The color bar represents 1 − p values corrected for multiple comparisons. (B) Scatterplot
PACAP38-LI is plottedagainst the average axial diffusivity under the significant voxels. Theboxplots stand formean, 95%confidence interval, and range.Outliers are
depicted with open circles. MNI = Montreal Neurological Institute; PACAP38-LI = pituitary adenylate cyclase-activating peptide 38-like immunoreactivity.
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multiple comparisons) (½F4 ﬁgure 4). We found no signiﬁcant
correlation with FA and RD.
Discussion
Herein, we report signiﬁcant correlation between diﬀusion
parameters of the white matter and interictal plasma
PACAP38-LI in patients with migraine in the occipital white
matter. Similar to our former results,3 the interictal
PACAP38-LI was lower than in normal healthy controls.
Interpretation of diﬀusion measures in terms of microstruc-
tural characteristics is a much-debated area complicated by
the fact that microstructural properties are probed in a few
millimeter large elements of the space. However, it is generally
accepted that lower FA or higher MD corresponds to reduced
white matter integrity. AD and RD are suggested to correlate
with the number of axons and the integrity of the myelin,
respectively.32,33 As such, our results could be interpreted as
follows: abnormally lower plasma PACAP38 levels in the
interictal phase are accompanied by decreased values of MD,
AD, and RD representing higher axonal density and/or
myelination, or generally more compact white matter in the
optic radiation, corpus callosum, and temporoparietal regions.
The absence of correlation with FA may be attributable to the
fact that FA is a measure that combines AD and RD; if there is
a similar change in both AD and RD, FA would change only if
the magnitude of change is diﬀerent in the 2 perpendicular
directions.
Considering that interictal hyperexcitability of the cortex in
migraineurs has been demonstrated before,8,34 and this in-
creased baseline activity might also reveal to be maladaptive
plasticity leading to more compact white matter, our results
could be an indication of such maladaptive remodeling in
response to migraine symptoms that is in connection with
PACAPergic signaling. In particular, a functional MRI study
of PACAP38-induced migraine-like attacks found increased
connectivity of the left visual cortex in the default-mode
network.35 This increased connectivity and presumable ac-
tivity could also lead to increased structural connections.
Figure 3 Correlation of PACAP38-LI and perpendicular diffusivity
(A) The skeleton is overlaid in green on the mean fractional anisotropy image. Significant correlations are depicted in blue/light blue (maximum p value MNI
coordinates: x = 115, y = 64, z = 102). Clusters are thickened for better visualization. The color bar represents 1 − p values corrected formultiple comparisons.
(B) Scatterplot PACAP38-LI is plotted against the average perpendicular diffusivity under the significant voxels. The boxplots stand for mean, 95% confidence
interval, and range. Outliers are depictedwith open circles.MNI =Montreal Neurological Institute; PACAP38-LI = pituitary adenylate cyclase-activating peptide
38-like immunoreactivity.
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Of course, it might also be possible that the connection be-
tween PACAP38 and white matter integrity is purely co-
incidental and decreased interictal plasma PACAP38 levels
reﬂect changes in PACAPergic signaling that contribute to
disrupted neurochemical coupling in migraine, as demon-
strated by magnetic resonance spectroscopy studies.36 In the
long term, these functional alterations may prove to be
structural changes.
Longitudinal studies might help in understanding the exact
nature of these connections. The location of correlating dif-
fusion measurements suggests involvement of the visual
system, many aspects of which are aﬀected in migraine.37
Photophobia is a prominent accompanying symptom present
in a large percentage of migraineurs, and bright light is known
to exacerbate migrainous headache. The phenomenon is
thought to originate in part from intrinsically photosensitive
retinal ganglionic cells38 that express PACAP38 to be used as
a cotransmitter in retinohypothalamic projections.12,39,40
Neurons of the suprachiasmatic nucleus on the receiving end
of these pathways connect to and modulate light-sensitive
neurons in the trigeminal nucleus caudalis,41 an area that also
contains PACAP38-expressing neurons,42 thus providing
possible linkage between the visual and trigeminovascular
system. Intrinsically photosensitive retinal ganglionic cells
also show direct connections to thalamic pain centers in rats43
and have been thought to be part of a photophobia pathway
that involves direct stimulation of trigeminal aﬀerents in the
eye without interposition of the optic nerve.44,45
Other animal studies link PACAP38 to behavioral aspects of
photophobia: PACAP-deﬁcient mice, after nitroglycerol-
induced activation of the trigeminovascular system, exhibit
light avoidance to a lesser degree than their wild-type coun-
terparts.46 In light of the above, it is possible that reduced
interictal PACAP38 levels reﬂect changes in photophobia-
associated signaling that co-occur with alterations of ﬁber
integrity in the optic tract, which would also be corroborated
by the ﬁnding that PACAP38 uptake peaks in the occipital
cortices after intranasal administration in mice.17
The correlation between the white matter microstructural
measures and the PACAP38 immunoreactivity was somewhat
lateralized. Formerly, we showed that the diﬀusion charac-
teristics of subcortical structures are asymmetric,47 which
might be present in major white matter tracts as well.48 Al-
though they did not reach signiﬁcance when corrected for
multiple comparisons, there are voxels in the contralateral
white matter that mirror signiﬁcant results at a more liberal
statistical threshold.
The change in the pattern of correlating diﬀusion measure-
ments with the inclusion of disease duration as a nuisance
regressor suggests that altered PACAP38 metabolism and its
eﬀect might develop as a function of disease progression,
though it is unclear whether this is due to disease pathology or
accumulating eﬀects of allostatic load. In another study, we
found that longer disease duration corresponds with de-
creased values of AD in the left parietooccipital regions in
migraine patients with aura,22 which co-occur with
PACAP38-related alterations in the current study. Consid-
ering that decreased PACAP38 levels correlate with diﬀusion
measures of the left thalamus irrespective of disease duration,
we would suggest that PACAP38 might have a few diﬀerent
roles in the development of white matter alterations, which
should be addressed in further studies.
One limitation of our study is the heterogeneity of the pa-
tient population because of the inclusion of migraine
Figure 4 Correlation of pituitary adenylate cyclase-activat-
ing peptide 38-like immunoreactivity and axial
and mean diffusivity with disease duration as
nuisance regressor
The skeleton is overlaid in green on the mean fractional anisotropy image.
Significant correlations are depicted in red for axial diffusivity (A) and copper
formeandiffusivity (B) (maximum p valueMNI coordinates:meandiffusivity:
x = 98, y = 101, z = 85; axial diffusivity: x = 102, y = 96, z = 82). Clusters are
thickened for better visualization. The color bar represents 1 − p values
corrected for multiple comparisons. MNI = Montreal Neurological Institute.
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patients both with and without aura. Based on our recent
results, there are microstructural diﬀerences in the 2 groups
that would necessitate regarding them as separate entities.22
Hence, we repeated the analysis separately for patients with
and without aura. Since group sizes are considerably smaller,
no signiﬁcant correlation was found in either group with
interictal PACAP38-LI. However, looking at the un-
corrected results, we can identify similar patterns of corre-
lation in both groups (data available from Dryad [Material]:
doi.org/10.5061/dryad.g58811v), which would indicate no
major diﬀerences in terms of correlating PACAP38-LI and
diﬀusion measures. Still, studies deploying greater sample
sizes are needed to assess diﬀerences between migraine
patients with and without aura.
Also, since PACAPergic signaling seems to be altered in
migraine, we decided to focus our study on the in-
terindividual variation of PACAP38-LI in patients with
migraine. However, information about the relationship be-
tween PACAP38-LI and white matter diﬀusion measures in
healthy controls is rare in the literature. Controlled studies
are needed to assess possible diﬀerences in the relationship
between PACAP38 levels and microstructural character-
istics in healthy controls and migraineurs.
While various MRI measures are useful biomarkers of mi-
graine, direct connection between the disease and MRI fea-
tures is still to be established. Providing connection between
a pathobiologically important neurochemical biomarker of
the disease andMRI alterations found in migraine emphasizes
the value of both markers and opens up new directions of
investigations.
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